Bristol-Myers Squibb heads into its October 29 earnings date with options traders more defensive than they have been for most of the past year, even as short sellers quietly reduce their positions.
The clearest tension is in options. Put demand has risen meaningfully relative to calls, with the put/call ratio at 1.05, above its 20-day average of 0.99 and running close to the 52-week high of 1.12. The z-score of 0.86 is not extreme, but the direction of travel is notable: the PCR has climbed from around 0.90 in early September to above 1.05 through the final two weeks of the month. That shift points to investors adding downside protection as the print approaches, not panic, but a visible lean toward hedging.
Short interest tells a contrasting story. Bears have been trimming. BMY short interest fell roughly 1.3% over the week to 2.1% of the free float, and is down about 3.5% over the past month. The borrow market is entirely relaxed: availability is effectively uncapped, with over two billion shares available to lend, and the cost to borrow dropped sharply this week to just 0.21%, roughly half what it was a week ago and the lowest reading in the 30-day window. The ORTEX short score of 34.1 is low and barely moved across the past ten sessions. None of this is the profile of a stock where shorts are building a case.
The Street is broadly constructive, though not uniformly so. Piper Sandler raised its target to $82 on September 16, reiterating Overweight, and JPMorgan lifted to $73 after the July quarter results, maintaining its Overweight rating. HSBC raised to $65 but held at Hold, and Wells Fargo, RBC and Cantor Fitzgerald all raised targets while sitting in neutral or sector-perform territory. The mean analyst target is around $67, implying modest upside from the current $62.86. The bull case centres on growth in Opdivo, Qvantig and Eliquis, with analysts pointing to a 10-15% Eliquis growth target for the year and potential upside from pipeline readouts. The bear case is more structural: around 70% of BMY revenues come from the US, leaving the company exposed to pricing and policy risk, and competition in core therapeutic areas remains a persistent concern. At roughly 9.4x trailing earnings and 8.8x EV/EBITDA, valuation is undemanding for a large-cap pharma name. The dividend score ranks in the 99th percentile, reflecting the stock's income appeal, though the dividend history in the data does not extend beyond 2022.
One piece of third-party data adds texture without being a leading indicator. Medicaid reimbursements tied to BMY products fell 26% year on year in Q1 2026, with Medicaid prescription volumes down 11% over the same period, according to CMS data published by ORTEX Alt Data. Neither dataset has been measured to lead the company's reported figures, so this is colour rather than a signal. It does, however, illustrate the pricing and volume pressure the bears flag in their thesis.
On the ownership side, the top holders are all passive giants. BlackRock held 8.8% of shares as of August 31, with Vanguard and State Street also among the largest registered positions. T. Rowe Price stands out with a last reported increase of over 21 million shares, a material addition. There are no 13D activist filings on the register, and the most recent insider activity is limited to compensation-related exercises and modest discretionary sales, most notably a September 9 open-market sale of around 6,250 shares by the Chief Medical Officer worth roughly $403,000. Net insider activity over the past 90 days is marginally negative in both shares and value, neither a meaningful signal in either direction.
The two prior quarterly earnings prints saw BMY gain 3.5% the day after its July 2026 results and fall 1.4% after May 2026 results, a narrow and inconsistent pattern. The stock is down around 5.6% over the past month, closing at $62.86, while close peers PFE and MRK gained 2.8% and were flat on the week respectively, suggesting BMY is carrying some stock-specific softness. The question heading into October 29 is whether the pipeline progress the bulls are counting on shows up clearly enough in the numbers to shift the options lean back toward neutral.
See the live data behind this article on ORTEX.
Open BMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
